“With a pipeline of incretins in clinical development and deep scientific expertise in this space, Lilly is well positioned to match the biologic properties of specific molecules to the desired ...
Hosted on MSN1mon
Novo, Eli Lilly to dominate global pharma sales in 2025: reportBlockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback